Petros Pharmaceuticals assigns subsidiary assets (Metuchen, Timm, Pos-T-Vac) to creditor trust

Petros Pharmaceuticals, Inc.

Effective June 16, 2025, Petros assigned all assets of subsidiaries Metuchen, Timm Medical, and Pos-T-Vac to a third-party fiduciary for benefit of creditors.
The Vivus License Agreement for Stendra® was terminated March 31, 2025; Petros lost all rights to Stendra in the Licensed Territory.
Pro forma balance sheet shows stockholders' equity of $8.0M as of March 31, 2025, reflecting deconsolidation, warrant exercises, and redemptions.
Subsidiaries' operations classified as discontinued; deconsolidation from Petros' balance sheet expected in Q2 2025.

item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.